Ninsun Biotech SA
Targeting cancer stem cells for theranostic applications.
Ninsun Biotech provides the first clinically validated test that specifically measures cancer stem cells (CSCs) to reveal the true aggressiveness of lung tumors and predict immunotherapy failure before treatment even starts.
While imaging only shows tumor size, our CE-marked test quantifies CSC-driven immune escape from a single biopsy, fitting seamlessly into routine pathology workflows.
We already validated prognosis on over 300 patients with leading cancer centers and are now unlocking predictive immunotherapy response with the same assay.
Our technology enables oncologists to avoid ineffective therapies, improve survival and reduce costs.
Ninsun Biotech is redefining precision oncology by staying ahead of cancer, from day one.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
01.06.2025
capital venture
15.01.2025
FIT
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Ninsun Biotech SA
Targeting cancer stem cells for theranostic applications.
Headquarter:
Monthey
Foundation Date:
March 2025
Technology:
- Biotech
Sectors:
- Cancer
- Diagnostics
- Drug discovery
Support received
